Filtered By:
Specialty: Health Management
Drug: Plavix
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Abstract
As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures rivaroxaban (Xarelto, Bayer) to submit evidence of the clinical and cost effectiveness of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome (ACS). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence for the clinical and cos...
Source: PharmacoEconomics - December 21, 2015 Category: Health Management Source Type: research
Sequential Value-of-Information Assessment for Prospective Drug Safety Monitoring Using Claims Databases: The Comparative Safety of Prasugrel v. Clopidogrel
Conclusion. The proposed approach integrates expected health harms and benefits of continued monitoring in the decision to raise a safety alert.
Source: Medical Decision Making - September 18, 2013 Category: Health Management Authors: Patrick, A. R., Franklin, J. M., Weinstein, M. C., Glynn, R. J., Schneeweiss, S. Tags: Original Articles Source Type: research
